The Effects of FK778 in combination with tacrolimus and steroids: A phase II multicenter study in renal transplant patients

Transplantation

Volumn 78, Issue 1, 2004, Pages 9-14

  Vanrenterghem, Yves ^a   Van Hooff, Johannes P ^b   Klinger, Marian ^c   Wlodarczyk, Zbigniew ^d   Squifflet, Jean Paul ^e   Mourad, Georges ^f   Neuhaus, Peter ^g   Jurewicz, Adam ^h   Rostaing, Lionel ⁱ   Charpentier, Bernard ^j   Pa̧czek, Leszek ^k   Kreis, Henri ^l   Chang, Rene ^m   Paul, Leendert C ⁿ   Grinyó, Josep M ^o   Short, Colin ^p  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d Samodzielny Publiczny Szpital Klin   (Poland)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f LAPEYRONIE HOSPITAL   (France)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

ⁱ CHU RANGUEIL   (France)

^j BICÊTRE HOSPITAL   (France)

^k MEDICAL UNIVERSITY OF WARSAW   (Poland)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m ST GEORGE S HOSPITAL   (United Kingdom)

ⁿ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^o HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^p MANCHESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

Acute rejections; Immunosuppressive drugs; Kidney transplantation; Malonitrilamides; Tacrolimus

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; CHOLESTEROL; CORTICOSTEROID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BIOPSY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REFLUX ESOPHAGITIS; SIDE EFFECT; VASCULAR DISEASE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALKYNES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NITRILES; PATIENT COMPLIANCE; PREDNISOLONE; TACROLIMUS; TREATMENT OUTCOME;

EID: 3142734960     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000132562.54089.62     Document Type: Article

References (17)

1. Waer M. Leflunomide, malonitrilamides, and transplant immunology. Transplant Rev 1998; 12: 156.
2. Vu MD, Qi S, Wang X, et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. Transplantation 2003; 75: 1455-1459.
3. Schorlemmer HU, Kurrle R, Schleyerbach R. Leflunomide's active metabolite A77-1726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytes. Int J Immunother 1998; 14: 213-222.
4. Slauson SD, Silva HT, Sherwood SW, Morris RE. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett 1999; 67: 79-183.
5. Savikko J, von Willebrand E, Häyry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential application for restenosis and chronic rejection. Transplantation 2003; 76: 455-458.
6. Pinschewer DD, Ochsenbein AF, Fehr T, et al. Leflunomide-mediated suppression of antiviral antibody and T cell responses: differential restoration by uridine. Transplantation 2001; 72: 712-719.
7. Schorlemmer HU. Development of a novel drug for transplantation: current results and future perspectives. Transplant Proc 2001; 33: 2425-2428.
8. Lindner JK, Zantl L. Synergism of the malonitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Transpl Int 1998; 11: 303-309.
9. Qi Z, Simanaitits M, Ekberg H. Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts. Transpl Immunol 1999; 7: 169-175.
10. Williams JW. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential application for restenosis and chronic rejection. Transplantation 2003; 76: 471-473.
11. Snoeck R, Andrei G, Lilja HS, et al. Activity of malononitrilamide compounds against murine and simian polyomavirus. 5th International Conference on New Trends in Clinical and Experimental Immunosuppression; 2002 Febr. 7-10; Geneva, Switzerland, p. 38.
12. Zeng H, Knight D, Chong A, et al. Cytomegalovirus (CMV) antiviral activity of the malonitrilamide, FK778. Am J Transplant 2003; 3(Suppl 5): 393.
13. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-23.
14. Cianco G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100-1106.
15. van Hooff JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal transplant recipients. Transplantation 2003; 75: 1934-1939.
16. Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429-435.
17. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358-366.